Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Clinical Oncology

• Publication date

  2016-10-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2016.68.1585PMID 27573663
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Single agent carboplatin for pediatric low‐grade glioma: A retrospective analysis shows equivalent efficacy to multiagent chemotherapy

  2016cited by this paper
• A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation

  2015cited by this paper
• Advances in the Management of Low-Grade Gliomas

  2014cited by this paper
• Pediatric low-grade gliomas: how modern biology reshapes the clinical field.

  2014cited by this paper
• Targeted Therapy in Pediatric Low-Grade Glioma

  2014cited by this paper
• Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas

  2013cited by this paper
• Optic pathway gliomas in adolescence--time to challenge treatment choices?

  2013cited by this paper
• Sustained Response to Weekly Vinblastine in 2 Children With Pilomyxoid Astrocytoma Associated With Diencephalic Syndrome

  2013cited by this paper
• Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma.

  2012cited by this paper
• Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology.

  2012cited by this paper
• Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas.

  2012cited by this paper
• Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group.

  2012cited by this paper
• BRAF-KIAA1549 Fusion Predicts Better Clinical Outcome in Pediatric Low-Grade Astrocytoma

  2011cited by this paper
• Feasibility and efficacy of repeated chemotherapy for progressive pediatric low‐grade gliomas

  2011cited by this paper
• Does chemotherapy affect the visual outcome in children with optic pathway glioma? A systematic review of the evidence.

  2010cited by this paper
• Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas

  2009cited by this paper
• The PedsQL™ brain tumor module: Initial reliability and validity

  2007cited by this paper
• The role of telomere maintenance in the spontaneous growth arrest of pediatric low-grade gliomas.

  2006cited by this paper
• Weekly vinblastine in pediatric low‐grade glioma patients with carboplatin allergic reaction

  2005cited by this paper
• Chemotherapy for Progressive Low-Grade Gliomas in Children Older than Ten Years: The Dana-Farber Experience

  2003cited by this paper
• High response rate to cisplatin/etoposide regimen in childhood low-grade glioma.

  2002cited by this paper
• Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood.

  1993cited by this paper
• Results of the treatment of children with recurrent gliomas with lomustine and vincristine

  1988cited by this paper
• Response to vincristine of recurrent brain tumors in children.

  1976cited by this paper

• From Diagnosis Delay to Targeted Therapy: A Retrospective Study of Pediatric DLGNT with a Comprehensive Literature Review.

  2026cites this paper
• Diencephalic Syndrome: Clinical Features, Pathophysiology, and Long-Term Outcomes.

  2026cites this paper
• Molecular convergence enables precision medicine for pediatric low grade gliomas.

  2026cites this paper
• Multiclass machine learning models for molecular subtype identification of pediatric low-grade glioma using bi-institutional MRIs for precision medicine

  2025cites this paper
• Targeted therapy for pediatric glioma: RAF(t)ing in the molecular era

  2025cites this paper
• Decoding Optic Pathway Gliomas: Molecular Insights and Emerging Therapies.

  2025cites this paper
• Incidence of Bevacizumab‐Associated Toxicity in Children With Low‐Grade Glioma With and Without Neurofibromatosis Type 1

  2025cites this paper
• Real-world pharmacokinetics of trametinib in pediatric low-grade glioma

  2025cites this paper
• IDH-mutant gliomas in children and adolescents - from biology to clinical trials

  2025cites this paper
• Predictors in Optic Pathway Gliomas in Neurofibromatosis Type 1: A Single Center Study

  2025influential citation
• Integrating MAPK pathway inhibition into standard-of-care therapy for pediatric low-grade glioma

  2025cites this paper
• Carboplatin and vinblastine monthly in the optic pathway and hypothalamic gliomas: A retrospective analysis in a single institute

  2025cites this paper
• Unraveling novel variants in the NF1 gene and investigating potential therapeutic strategies

  2025cites this paper
• Deep learning volumetrics reveal distinct clinical trajectories for pediatric low-grade gliomas under surveillance: A multicenter study

  2025cites this paper
• Head-to-head preclinical treatment design prioritizes promising therapies for neurofibromatosis type 1 optic glioma clinical translation

  2025cites this paper
• A Retrospective, Nationwide, Multicenter Study on Diagnosis and Treatment Outcome of Pediatric Optic Pathway/Hypothalamic Gliomas Including Analysis of Risk Factors for Progression After Systemic Anticancer Therapy

  2025cites this paper
• Molecular diagnostic factors, prognostic implications, and long-term outcomes in pediatric pilocytic astrocytoma.

  2025cites this paper
• Semisynthetic indole alkaloids restrain the invasiveness of glioblastoma cell lines and inhibit human Aquaporin-1 water channels.

  2025cites this paper
• Racemic Meroterpenoid with a 6/6/4/6/6/10/3 Skeleton via [2 + 2] and [4 + 2] Coupling of Sesquiterpenoid and Pyrone Units.

  2025cites this paper
• Myelodysplastic syndrome-post cytotoxic therapy for pediatric low-grade glioma

  2025cites this paper
• Significant clinical and radiologic response to targeted therapy in pediatric cervicomedullary low-grade gliomas harboring the BRAFV600E mutation

  2025cites this paper
• Old Tools in a New Era: The Continued Relevance of Chemotherapy in Pediatric Neuro-Oncology

  2025cites this paper
• Analysis of brain necrosis and secondary cancers after proton beam therapy for pediatric intracranial tumors: a single-center retrospective study

  2025cites this paper
• What Child Neurologists Need to Know About Pediatric Glioma.

  2025cites this paper
• Pediatric-Type Diffuse Low-Grade Gliomas: A Subgroup Defined by Peculiar Molecular Features and Distinct Prognostic Outcomes

  2025cites this paper
• LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration

  2024cites this paper
• Targeted Glioma Therapy—Clinical Trials and Future Directions

  2024cites this paper
• Considering Functional Outcomes as Efficacy Endpoints in Pediatric Low-Grade Glioma Clinical Trials: An FDA Educational Symposium.

  2024cites this paper
• Pediatric neuro-oncology: Highlights of the last quarter-century

  2024cites this paper
• Non‐alkylating agents‐induced gonadotoxicity in pre‐pubertal males: Insights on the clinical and pre‐clinical front

  2024cites this paper
• Improving Deep Learning Models for Pediatric Low-Grade Glioma Tumours Molecular Subtype Identification Using MRI-based 3D Probability Distributions of Tumour Location

  2024cites this paper
• Pilocytic astrocytoma: The paradigmatic entity in low‑grade gliomas (Review)

  2024cites this paper
• Very long-term outcomes of pediatric patients treated for optic pathway gliomas: A longitudinal cohort study.

  2024cites this paper
• Canadian Consensus for Treatment of BRAF V600E Mutated Pediatric and AYA Gliomas

  2024cites this paper
• Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology consensus review on diagnosis, management, and future directions.

  2024cites this paper
• Targeting the RAS/MAPK pathway in children with glioma

  2024cites this paper
• Understanding diffuse leptomeningeal glioneuronal tumors

  2024cites this paper
• BRAF/MEK inhibitors use for pediatric gliomas; real world experience from a resource-limited country

  2024cites this paper
• Optic pathway gliomas in children: Clinical characteristics, treatment, and outcome of 95 patients in a single center over a 31‐year period. Can we avoid radiotherapy?

  2024cites this paper
• Dissecting the Natural Patterns of Progression and Senescence in Pediatric Low-Grade Glioma: From Cellular Mechanisms to Clinical Implications

  2024cites this paper
• Future perspective of targeted treatments in pediatric low-grade glioma (pLGG): the evolution of standard-of-care and challenges of a new era

  2024cites this paper
• Carboplatin desensitization in the era of target therapies: still worthwhile?

  2024cites this paper
• Continuous response despite reduced dose of trametinib as single agent in an adolescent with a relapsed disseminated pediatric low-grade glioma KIAA1549-BRAF fusion positive: a case report and review of the literature

  2024cites this paper
• Low-grade glioma in children with neurofibromatosis type 1: surveillance, treatment indications, management, and future directions

  2024cites this paper
• Immunotherapy for pediatric low-grade gliomas

  2024cites this paper
• Adaption of neurosurgical resection patterns for pediatric low‐grade glioma spanning two decades—Report from the German LGG‐studies 1996–2018

  2024cites this paper
• European Standard Clinical Practice Recommendations for primary Pediatric Low-grade Gliomas

  2024cites this paper
• Predicting response to chemotherapy in brain tumor patients based on MRI features.

  2024cites this paper
• Chemotherapy in pediatric low-grade gliomas (PLGG)

  2024influential citation
• Second-look surgery in postoperative pediatric low-grade glioma

  2024cites this paper
• Type II RAF inhibitor tovorafenib for the treatment of pediatric low-grade glioma

  2024cites this paper
• Visual Deficits and Diagnostic and Therapeutic Strategies for Neurofibromatosis Type 1: Bridging Science and Patient-Centered Care

  2024cites this paper
• The role of reoperation in pediatric cerebellar pilocytic astrocytoma.

  2024cites this paper
• How modern treatments have modified the role of surgery in pediatric low-grade glioma

  2024cites this paper
• Advances in pediatric gliomas: from molecular characterization to personalized treatments

  2024cites this paper
• Pediatric-type low-grade gliomas in adolescents and young adults—challenges and emerging paradigms

  2024cites this paper
• Case report: Pediatric low-grade gliomas: a fine balance between treatment options, timing of therapy, symptom management and quality of life

  2024cites this paper
• Cell cycle dysregulation in cancer.

  2024cites this paper
• Treatment of Pediatric Low-Grade Gliomas

  2023cites this paper
• Consensus framework for conducting phase I/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the International Pediatric Low-Grade Glioma Coalition Clinical Trial Working Group.

  2023cites this paper
• Bevacizumab as Single Agent in Children and Teenagers with Optic Pathway Glioma

  2023cites this paper
• A new era for optic pathway glioma: A developmental brain tumor with life-long health consequences

  2023cites this paper
• Pediatric low-grade glioma: State-of-the-art and ongoing challenges.

  2023cites this paper
• Brain Tumors in Adolescents and Young Adults: A Review

  2023cites this paper
• Optic Pathway Gliomas in Pediatric Population—Current Approach in Diagnosis and Management: Literature Review

  2023cites this paper
• BRAF-mediated brain tumors in adults and children: A review and the Australian and New Zealand experience

  2023cites this paper
• The Drosophila blood–brain barrier regulates sleep via Moody G protein-coupled receptor signaling

  2023cites this paper
• Comparison of the clinical features and treatment outcomes of pilocytic astrocytoma in pediatric and adult patients

  2023cites this paper
• Pediatric Optic Pathway Gliomas: A Report From Northern Greece

  2023cites this paper
• Optic Pathway Gliomas: The Trends of Basic Research to Reduce the Impact of the Disease on Visual Function.

  2023cites this paper
• A Molecular Update and Review of Current Trials in Paediatric Low-Grade Gliomas

  2023influential citation
• Pediatric diencephalic tumors: a constellation of entities and management modalities

  2023cites this paper
• Pediatric Central Nervous System Tumor Overview and Emerging Treatment Considerations

  2023influential citation
• Children's Oncology Group's 2023 blueprint for research: Central nervous system tumors

  2023cites this paper
• Unlocking the power of precision medicine for pediatric low-grade gliomas: molecular characterization for targeted therapies with enhanced safety and efficacy

  2023cites this paper
• Research of active compounds from Allii Macrostemonis Bulbus and potential targets against Non-Hodgkin's Lymphoma based on Network pharmacology.

  2023cites this paper
• Neurofibromatosis type1, type 2, tuberous sclerosis and Von Hippel-Lindau disease

  2023cites this paper
• Optic pathway and hypothalamic glioma, old problems, new paradigms

  2023cites this paper
• Use of Trametinib in Children and Young Adults With Progressive Low-grade Glioma and Glioneuronal Tumors

  2022cites this paper
• Optic Pathway Glioma in Children with Neurofibromatosis Type 1: A Multidisciplinary Entity, Posing Dilemmas in Diagnosis and Management Multidisciplinary Management of Optic Pathway Glioma in Children with Neurofibromatosis Type 1

  2022cites this paper
• Integrated response analysis of pediatric low-grade gliomas during and after targeted therapy treatment

  2022cites this paper
• Growth Hormone Replacement Therapy Seems to Be Safe in Children with Low-Grade Midline Glioma: A Series of 124 Cases with Review of the Literature

  2022cites this paper
• Pediatric low-grade glioma: Targeted therapeutics and clinical trials in the molecular era

  2022cites this paper
• Novel “T-Dimension” Therapies for Pediatric Optic Pathway Glioma: A Timely, Targeted, and Tailored Treatment Trend

  2022cites this paper
• Medical Treatment of Pediatric Low-Grade Glioma

  2022cites this paper
• Clinical and economic impact of molecular testing for BRAF fusion in pediatric low-grade Glioma

  2022cites this paper
• Efficacy of different salvage regimens in progressive unresectable pediatric low-grade glioma

  2022influential citation
• Management of Optic Pathway Glioma: A Systematic Review and Meta-Analysis

  2022cites this paper
• Clinical trials targeting neurofibromatoses-associated tumors: a systematic review

  2022cites this paper
• Identifying risk factors for recurrence/relapse in NF1 optic pathway gliomas: Moving forward by looking back.

  2022cites this paper
• Cytochrome C as a potential clinical marker for diagnosis and treatment of glioma

  2022cites this paper
• Improving Deep Learning Models for Pediatric Low-Grade Glioma Tumors Molecular Subtype Identification Using 3D Probability Distributions of Tumor Location

  2022cites this paper
• The first-in-class ERK inhibitor ulixertinib shows promising activity in MAPK-driven pediatric low-grade glioma models.

  2022cites this paper
• Characteristics and trends of globally registered glioma clinical trials in the past 16 years

  2022cites this paper
• MR Imaging of Pediatric Low-Grade Gliomas: Pretherapeutic Differentiation of BRAF V600E Mutation, BRAF Fusion, and Wild-Type Tumors in Patients without Neurofibromatosis-1

  2022cites this paper
• Eano-Euracan-Sno Guidelines on Circumscribed Astrocytic GLIOMAS, Glioneuronal and Neuronaltumors.

  2022cites this paper
• A cuproptosis-related lncRNAs signature for prognosis, chemotherapy, and immune checkpoint blockade therapy of low-grade glioma

  2022cites this paper
• Molecular Engines, Therapeutic Targets, and Challenges in Pediatric Brain Tumors: A Special Emphasis on Hydrogen Sulfide and RNA-Based Nano-Delivery

  2022cites this paper
• The Identification of Necroptosis-Related Subtypes, the Construction of a Prognostic Model, and the Characterization of the Tumor Microenvironment in Gliomas

  2022cites this paper
• The evolving landscape of pilocytic astrocytoma: a bibliometric analysis of the top-100 most cited publications

  2022cites this paper